Glycation affects fibril formation of Aβ peptides

J Biol Chem. 2018 Aug 24;293(34):13100-13111. doi: 10.1074/jbc.RA118.002275. Epub 2018 Jun 29.

Abstract

Increasing evidence shows that β-amyloid (Aβ) peptides, which are associated with Alzheimer disease (AD), are heavily glycated in patients, suggesting a role of this irreversible nonenzymatic post-translational modification in pathology. Previous reports have shown that glycation increases the toxicity of the Aβ peptides, although little is known about the mechanism. Here, we used the natural metabolic by-product methylglyoxal as a glycating agent and exploited various spectroscopic methods and atomic force microscopy to study how glycation affects the structures of the Aβ40 and Aβ42 peptides, the aggregation pathway, and the morphologies of the resulting aggregates. We found that glycation significantly slows down but does not prevent β-conversion to mature fibers. We propose that the previously reported higher toxicity of the glycated Aβ peptides could be explained by a longer persistence in an oligomeric form, usually believed to be the toxic species.

Keywords: Alzheimer disease; aggregation; amyloid plaques; beta-amyloid; carbohydrate; carbohydrates; fibril formation; glycation; glycobiology; glycosylation; neurodegeneration; protein aggregation; structural biology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease*
  • Amino Acid Sequence
  • Amyloid / chemistry*
  • Amyloid beta-Peptides / chemistry*
  • Amyloid beta-Peptides / metabolism
  • Glycosylation
  • Humans
  • Peptide Fragments / chemistry*
  • Peptide Fragments / metabolism
  • Protein Aggregation, Pathological*
  • Protein Conformation
  • Protein Processing, Post-Translational*
  • Sequence Homology

Substances

  • Amyloid
  • Amyloid beta-Peptides
  • Peptide Fragments
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (1-42)